AstraZeneca PLC (AZN) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	61.4B	58.7B	54.1B	45.8B	44.4B
Cost of Revenue	11.1B	10.6B	10.2B	8.3B	12.4B
Gross Profit	50.2B	48.1B	43.9B	37.5B	32.0B
Operating Expenses
R&D Expense	15.1B	14.2B	13.6B	10.9B	9.8B
SG&A Expense	21.7B	20.5B	20.2B	18.2B	18.0B
General & Admin Expense	21.1B	19.9B	19.7B	17.7B	17.4B
Selling & Marketing Expense	587.0M	579.0M	555.0M	539.0M	536.0M
Other Expenses	(530.0M)	(381.0M)	56.0M	193.0M	457.0M
Total Operating Expenses	36.3B	34.4B	33.9B	29.4B	28.2B
Cost and Expenses	47.4B	45.0B	44.1B	37.6B	40.6B
Operating Income (EBIT)	14.0B	13.7B	10.0B	8.2B	3.8B
Non-Operating
Interest Income	361.0M	360.0M	345.0M	301.0M	81.0M
Interest Expense	1.7B	1.7B	1.7B	1.6B	1.3B
Net Interest Income	(1.4B)	(1.3B)	(1.3B)	(1.3B)	(1.2B)
Other Non-Op Income/Expense	(1.4B)	(1.3B)	(1.3B)	(1.3B)	(1.3B)
Non-Operating Income (excl Interest)	(349.0M)	(353.0M)	(370.0M)	(295.0M)	(74.0M)
EBT (Pre-Tax Income)	12.6B	12.4B	8.7B	6.9B	2.5B
Income Tax Expense	2.1B	2.2B	1.6B	938.0M	(792.0M)
Bottom Line
Net Income	10.4B	10.3B	7.0B	6.0B	3.3B
Earnings from Cont. Ops	10.5B	10.2B	7.0B	6.0B	3.3B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	10.4B	10.3B	7.0B	6.0B	3.3B
Per Share
Basic EPS	$6.72	$6.60	$4.54	$3.81	$2.12
Diluted EPS	$6.66	$6.54	$4.50	$3.81	$2.11
Revenue Per Share	$39.57	$37.90	$34.89	$29.33	$28.65
Shares
Basic Shares Outstanding	1.6B	1.6B	1.6B	1.6B	1.5B
Diluted Shares Outstanding	1.6B	1.6B	1.6B	1.6B	1.6B
Profitability Metrics
EBITDA	20.7B	19.8B	15.4B	13.4B	9.1B
D&A	6.4B	5.7B	5.1B	4.9B	5.3B
EBIT	14.3B	14.1B	10.4B	8.5B	3.8B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026